Enanta Pharmaceuticals (ENTA) vs Keros Therapeutics (KROS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Keros Therapeutics (KROS) has outperformed Enanta Pharmaceuticals (ENTA) over the past year, losing 36.3% versus a loss of 40.1%. Over five years, KROS leads with a -80.2% price change compared with -91.7% for ENTA. Enanta Pharmaceuticals is the larger company by market cap ($222.2 million vs $217.4 million), about 1.0 times the size.
Keros Therapeutics converts more of its revenue into profit, with a net margin of 35.7% versus -108.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTA | KROS |
|---|---|---|
| Share price | $7.62 | $11.08 |
| Market cap | $222.19M | $217.44M |
| 1-day change | -4.51% | -2.72% |
| YTD return | -51.68% | -45.58% |
| 1-year return | -40.14% | -36.29% |
| 5-year return | -91.71% | -80.25% |
| EPS (TTM) | $-2.35 | $-2.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $63.00M | $243.86M |
| Revenue growth (YoY) | -3.56% | — |
| Net income (latest FY) | $-68.25M | $87.01M |
| Operating margin | -99.01% | 27.71% |
| Net margin | -108.33% | 35.68% |
| 52-week high | $17.15 | $22.55 |
| 52-week low | $7.56 | $8.98 |
| Distance from 52-week high | -55.57% | -50.86% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +186.48% | +78.97% |
| Average volume | 287.81K | 196.50K |
| Shares outstanding | 29.16M | 19.62M |
| Employees | 120 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Keros Therapeutics is more profitable, keeping 35.7 cents of every revenue dollar as net income versus -108.3 cents for Enanta Pharmaceuticals.
About Enanta Pharmaceuticals
ENTA stock →Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
About Keros Therapeutics
KROS stock →Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
ENTA vs KROS FAQ
Which is bigger, Enanta Pharmaceuticals or Keros Therapeutics?
Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $222.19M compared with $217.44M for Keros Therapeutics (KROS).
Which stock has performed better over the past year, ENTA or KROS?
KROS returned -36.29% over the past 12 months, compared with -40.14% for ENTA (price return, excluding dividends). Past performance does not predict future results.
Are Enanta Pharmaceuticals and Keros Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.